CrossAssetDataThe Company File
···
RPRX

Royalty Pharma plc

Royalty Pharma plc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $2.4 billion and a profit of $771 million (its filed statements).

Product business Pharmaceutical Preparations New York, NY filings since 2020 9 of 9 filed
Ask the desk about RPRX → Compare RPRX with ZTS → Price chart on TradingView ↗ Full EDGAR file ↗ Watch RPRX →

Sector peers: ZTSVRTXBHCELAN

6.3/10headline grade
vs its business-model standard
6.4/10past 7.2/10present 5.0/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 6.3 out of ten, 9 of 9 metrics filed: past 6.4 out of ten, present 7.2 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 6.2 out of ten. 1 warning event since 2020; the latest 2022-04-04. 61st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 6.9 out of ten. +4.1% a year over 8 filed years; profitable in 8 of 8. 69th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 5.8 out of ten. Share count grew 8.8% a year. 21% of cash flow returned. Insiders: 74 sales, 0 purchases. 58th percentile among 80 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Financial health (present): 7.3 out of ten. ROE 8%: 8¢ of profit per shareholder dollar. Leverage 50%: owes 50¢ per asset dollar. 73rd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.5 out of ten. top 25% of 314 in its family; net margin 32.4%. 75th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 6.4 out of ten. top 36% of 315 in its family for leadership; chief executive since 2020. 64th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 4.2 out of ten. bottom 42% of 272 in its family for room to expand. 42nd percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 6.1 out of ten. top 39% of 307 in its family for growth drivers. 61st percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 5.0 out of ten. bottom 50% of 234 in its family for expectations against reality. 50th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-11 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 144, 2026-10-05. Filings on record since 2020. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Financial Royalty Assets 95%, Royalty Income Other 5%. As tagged in its annual report (Form 10-K, filed 2026-02-11).

Who runs it

Legorreta, Pablo G. (CEO, Chairman of the Board); Hite, Christopher (EVP & Chairman, Partnering); Coyne, Terrance P. (EVP & CFO); Urist, Marshall (EVP, Research & Investments); Mcgivern, Arthur Richard (EVP, Investments & GC); Lloyd, George W. (EVP, Investments & CLO); Bassler, Bonnie L (director); Coric, Vlad (director); Engelbert, Catherine M. (director); Ho, Carole (director); and 4 more. 14 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.